Cannabis is a word familiar to all for many reasons but one is particular. An MoU was recently signed between Indian research institution, IIT-Kanpur and Niche Agriculture and Pharmaceuticals Limited (NAP Ltd.) to mutually research the cultivation of cannabis and it‘s many uses in pharma and bioengineering. The MoU further focuses on the exchange of academic materials and publications that formulate hemp-based medicines for chronic diseases.
As per government guidelines, cultivation of cannabis with more than 0.03% THC (Tetrahydrocannabinol) levels is barred across India.
About the research program
Cannabis is often used in medical spaces, especially to treat issues such as multiple sclerosis (MS) and nerve pain around the world and it also has references in Ayurveda. Widely known for its medical benefits, cannabis is often under scrutiny.
IIT-Kanpur & NAP Limited will together restructure the indigenous cannabis plant and develop new varieties of hemp seeds as per international policies and standards, and also offer people affordable medical treatment for chronic health problems.
Furthermore, the research will focus on improving cooperation between hemp cultivation and bioengineering to implement techniques like tissue culture.
India is facing a surge in medical conditions like cancer, epilepsy, migraine, chronic pain, arthritis, and insomnia. The development of alternate hemp based formulations could help doctors in the treatment of such severe medical conditions.
IIT-Kanpur to develop direct-to-mobile technology in India; proof-of-concept revealed
